Lipocine Inc. (LPCN): Price and Financial Metrics


Lipocine Inc. (LPCN)

Today's Latest Price: $1.59 USD

0.01 (0.63%)

Updated Nov 24 4:00pm

Add LPCN to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

LPCN Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for LPCN is 0.01 -- better than merely 9.18% of US stocks.
  • LPCN's price/sales ratio is 568.42; that's higher than the P/S ratio of 99.01% of US stocks.
  • The volatility of Lipocine Inc's share price is greater than that of 92.61% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Lipocine Inc are ONCT, ETON, HTBX, QUIK, and CDXS.
  • LPCN's SEC filings can be seen here. And to visit Lipocine Inc's official web site, go to www.lipocine.com.

LPCN Stock Price Chart Interactive Chart >

Price chart for LPCN

LPCN Price/Volume Stats

Current price $1.59 52-week high $2.39
Prev. close $1.58 52-week low $0.30
Day low $1.52 Volume 1,668,600
Day high $1.60 Avg. volume 2,151,882
50-day MA $1.41 Dividend yield N/A
200-day MA $1.09 Market Cap 104.44M

Lipocine Inc. (LPCN) Company Bio


Lipocine develops pharmaceutical products using its oral drug delivery technology in the areas of men’s and women’s health, with a current focus being testosterone replacement. The company was founded in 1997 and is based in Salt Lake City, Utah.


LPCN Latest News Stream


Event/Time News Detail
Loading, please wait...

LPCN Latest Social Stream


Loading social stream, please wait...

View Full LPCN Social Stream

Latest LPCN News From Around the Web

Below are the latest news stories about Lipocine Inc that investors may wish to consider to help them evaluate LPCN as an investment opportunity.

Lipocine under pressure on extended timeline for FDA review of Tlando application

The FDA has informed Lipocine (LPCN) that it needs more time to complete its review of the company's marketing application for oral testosterone replacement therapy Tlando (testosterone undecanoate). The agency's action date was today.Management says the FDA did not provide a new action date but stated that the review should...

Seeking Alpha | August 28, 2020

The Daily Biotech Pulse: Modrerna Japanese Vaccine Deal Talk, Lipocine FDA Decision, Liver Congress Presentations

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 27) Abbott Laboratories (NYSE: ABT)( announced emergency use authorization for an affordable …

Benzinga | August 28, 2020

Thinking about buying stock in UnitedHealth, VBI Vaccines Inc, ADMA Biologics, Qutoutiao, or Lipocine Inc?

NEW YORK, Aug. 28, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for UNH, VBIV, ADMA, QTT, and LPCN. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….

PR Newswire | August 28, 2020

Thinking about buying stock in Northern Dynasty Minerals, Fluent Inc, Lipocine Inc, NetApp Inc., or HP?

NEW YORK, Aug. 27, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NAK, FLNT, LPCN, NTAP, and HPQ. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….

PR Newswire | August 27, 2020

Lipocine EPS misses by $0.06

Lipocine (LPCN): Q2 GAAP EPS of -$0.13 misses by $0.06.Unrestricted cash, cash equivalents and marketable investment securities of $18.3M.Press Release...

Seeking Alpha | August 6, 2020

Read More 'LPCN' Stories Here

LPCN Price Returns

1-mo 19.55%
3-mo -3.64%
6-mo 74.04%
1-year 274.12%
3-year -56.32%
5-year -88.17%
YTD 313.09%
2019 -70.39%
2018 -62.21%
2017 -6.52%
2016 -71.54%
2015 145.82%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7768 seconds.